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Abstract
Background: Typically, women in South Africa (SA) are diagnosed with breast cancer when they self-present with
symptoms to health facilities. The aim of this study was to determine the pathway that women follow to breast
cancer care and factors associated with this journey.
Methods: A cross-sectional study was conducted at a tertiary hospital in the Western Cape Province, SA, between
May 2015 and May 2016. Newly diagnosed breast cancer patients were interviewed to determine their socio-
demographic profile; knowledge of risk factors, signs and symptoms; appraisal of breast changes; clinical profile
and; key time events in the journey to care. The Model of Pathways to Treatment Framework underpinned the
analysis. The total time (TT) between a woman noticing the first breast change and the date of scheduled treatment
was divided into 3 intervals: the patient interval (PI); the diagnostic interval (DI) and the pre-treatment interval (PTI).
For the PI, DI and PTI a bivariate comparison of median time intervals by various characteristics was conducted using
Wilcoxon rank-sum and Kruskal-Wallis tests. Cox Proportional-Hazards models were used to identify factors independently
associated with the PI, DI and PTI.
Results: The median age of the 201 participants was 54 years, and 22% presented with late stage disease. The median
TT was 110 days, with median patient, diagnostic and pre-treatment intervals of 23, 28 and 37 days respectively. Factors
associated with the PI were: older age (Hazard ratio (HR) 0.59, 95% CI 0.40–0.86), initial symptom denial (HR 0.43, 95% CI
0.19–0.97) and waiting for a lump to increase in size before seeking care (HR 0.51, 95% CI 0.33–0.77). Women with
co-morbidities had a significantly longer DI (HR 0.67, 95% CI 0.47–0.96) as did women who mentioned denial of initial
breast symptoms (HR 4.61, 95% CI 1.80–11.78). The PTI was associated with late stage disease at presentation (HR 1.78,
95% CI 1.15–2.76).
Conclusion: The Model of Pathways to Treatment provides a useful framework to explore patient’s journeys to care and
identified opportunities for targeted interventions.
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Background
Breast cancer, the commonest cancer among women
worldwide, is a major and growing public health burden.
Incidence rates have increased steadily since 2008 and
currently 1.7 million new cases are diagnosed each year
[1, 2]. In 2012 the majority (53%) of new breast cancer
cases were among women living in low- and middle-
income countries (LMICs) [1, 2], where the shift toward
more affluent lifestyles, particularly those associated with
dietary and reproductive risk factors, has been associated
with a rising burden of cancers. Lack of early detection
programs and poor access to treatment, place women in
LMICs at a high cancer mortality risk.
Breast cancer is the commonest cancer among women
in South Africa (SA) with an age-standardized incidence
rate of 35 per 100,000 women [3]. SA does not have a
* Correspondence: Jennifer.Moodley@uct.ac.za
1Cancer Research Initiative, Faculty of Health Sciences, University of Cape
Town, Anzio Road, Observatory, 7925, Cape, Town, South Africa
2Women’s Health Research Unit, School of Public Health and Family
Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road,
Observatory, 7925, Cape, Town, South Africa
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Moodley et al. BMC Cancer  (2018) 18:312 
https://doi.org/10.1186/s12885-018-4219-7
national mammography-screening program. Typically,
women with breast symptoms self-present to primary
health care facilities and are referred to secondary or ter-
tiary level health facilities if further diagnostic work-up
and treatment is required [4]. Minimizing time to diag-
nosis is dependent on timely presentation to primary
health care providers by women with symptoms suggest-
ive of breast cancer; appropriate assessment at the pri-
mary health care level and; timely access to referral and
treatment centres. For people with potential symptoms
of cancer the journey to cancer diagnosis is complex and
influenced by a multitude of factors including: know-
ledge and awareness of cancer symptoms; the nature of
the symptoms; perception of risk and; health system,
psychological, and socio-cultural barriers to health care
[5–14]. Understanding the influence of these factors on
the pathway women follow to breast cancer diagnosis is
vital to the development of locally relevant, targeted in-
terventions. Little is known about the pathway that
women follow to breast cancer diagnosis and treatment
in SA.
Theoretical frameworks provide a systematic approach
to understanding health behavior and there have been
calls for greater theoretical underpinning of help-seeking
research [15–17]. The Model of Pathways to Treatment
provides a useful research framework to explore and
understand patient’s journeys as it takes into account the
complex and dynamic nature of help-seeking behavior
[16, 17]. The Model identifies five key events in the
pathway to care: detection of bodily changes; perceived
reasons to discuss symptoms with a health care provider;
first consultation with a health care provider; diagnosis
and start of treatment, and four important intervals be-
tween these events: the appraisal, help-seeking, diagnos-
tic and the pre-treatment intervals [16]. The Model also
identifies 3 main types of contributing factors that influ-
ence the timing of events and duration of intervals.
These include patient (e.g. socio-demographics), health
system (e.g. access to health care) and disease-related
factors (e.g. site, growth-rate). By increasing understand-
ing of the factors influencing the key events in the path-
way to care, the model can be used to identify targets
for interventions in order to encourage early detection,
presentation, and treatment. Using the Model of Path-
ways to Treatment framework, we explored patient’s
pathways from breast cancer symptom discovery to
treatment, detailing time intervals and factors influen-
cing these intervals.
Methods
Study design, study site and sample size
A cross-sectional study was conducted at a tertiary hos-
pital in the Western Cape Province, SA, between May
2015 and May 2016. The hospital has an open-access,
one-stop diagnostic breast clinic where women may
present with a letter from a primary level provider
(nurse practitioner or doctor). The breast clinic provides
a same day clinical and cytological evaluation with refer-
ral to the Combined Breast Clinic (CBC) if the breast cy-
tology is positive for malignancy. Participants were
recruited from the CBC where a multidisciplinary clin-
ical team of surgeons, oncologists, radiologists and pa-
thologists, review new patients to make a definitive
breast cancer diagnosis and develop a management plan.
Based on clinic records we anticipated that 500 new
breast cancer patients would be seen over a 1-year
period. The sample size calculation was based on the
proportion of women expected to have a > 3-month dur-
ation from symptom discovery to treatment (delayed
presentation). Based on the literature we predicted that
60% of women would have a delayed presentation. To
estimate the proportion to within 5% of the true value
with a 95% confidence interval, a sample size of 213 was
required.
Data collection
Breast cancer patients were interviewed within 2 weeks
of diagnosis by a trained interviewer using a structured
questionnaire (Additional file 1), with relevant clinical
information retrieved from the hospital records. Information
was collected on: the socio-demographic profile of partici-
pants; knowledge of risk factors, signs and symptoms with
questions derived from the Breast Cancer Awareness
Measure [18]; breast habits and beliefs; appraisal of
breast changes; the clinical profile and; key time events
in the journey to diagnosis and care.
Socio-demographic details included: age; main home
language; educational level; employment status; medical
aid membership; marital status and; household income
status as classified by the hospital (H0 = persons on so-
cial grant; H1 = individual income < $5366 per annum
(p.a.) or family income < $7667 p.a.; H2 = individual in-
come between $5367 and $19,168 p.a. or family income
between $7667 and $26,852 p.a.; and H3 = individual in-
come >$19,168 p.a. or family income > $26,852 p.a.)
Knowledge of breast cancer risk factors and signs was
ascertained by first asking an unprompted open-ended
question “Can you name as many risk factors of breast
cancer/signs of breast cancer that you can think of?”
This was followed by a set of prompted closed questions
to determine knowledge of specific risk factors and signs
e.g. Can you tell me if you think a lump in the breast is
a sign of breast cancer? Participants were asked to re-
spond with a “Yes, No or Don’t Know” to each specific
closed question. An unprompted composite knowledge
score was computed by combing the score for un-
prompted knowledge of risk factors and the score for
unprompted knowledge of signs of breast cancer, with a
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maximum score of 22. The categories for unprompted
knowledge were based on the distribution of the scores
and created so as to represent the upper and lower
ranges of scores as well as the central tendency. The
highest score for unprompted composite knowledge was
13. Based on the distribution of the scores, unprompted
composite knowledge was divided into 3 balanced cat-
egories: no knowledge (score 0), very little knowledge
(score < 4) and little knowledge (score ≥5).
Breast habits, symptom appraisal and pathways to
care variables and response options included: history of
breast self-examination (Yes/No); type of first breast
change noticed (open question responses coded as
lumps in the breast, lumps in the armpit, bleeding or
discharge from nipple, nipple changes, changes in
breast skin, changes in size or shape of breast, pain in
breast or armpit, other); appraisal of breast change
(open question responses coded as mention (Yes/No)
of: breast cancer, not serious, ignored symptom, denial,
other); reason to have symptom checked (open ques-
tion responses coded as mention (Yes/No) of: lump
increasing in size, pain, prompted by family/friend,
prompted by reading pamphlet/breast awareness event/
television program, concerned about changes/wanted
to make sure nothing was wrong, other); type of first
health care provider seen(public sector provider, private
sector provider, other).
Clinical variables included: family history of breast
cancer; menopausal status; parity; breastfeeding; hormo-
nal contraceptive and hormonal replacement use; alco-
hol and smoking habits; and participant reported history
of benign breast disease or of any co-morbidity e.g.
hypertension, diabetes mellitus. In addition, the follow-
ing information was abstracted from the clinical records:
histological diagnosis, hormonal receptor status (estro-
gen (ER), progesterone (PR) and human epidermal
growth factor (HER2)); and the tumour, node and me-
tastasis (TNM) status at diagnosis which was used to
classify patients as having early (I, II) or late stage (III or
IV) disease.
The total time (TT) between a woman noticing the
first breast change and the date of scheduled treat-
ment for breast cancer was divided into 3 intervals:
the patient interval (PI) defined as the time between
date of first breast change to date of first health care
provider consultation; the diagnostic interval (DI)
which was the time between the first health care pro-
vider visit and the date of diagnosis and; the pre-
treatment interval (PTI), defined as the time between
the date of diagnosis and the date treatment was due
to commence. A calendar prompt was used to assist
participants’ memory of key dates and events. Date of
diagnosis was defined as the date that a clinical diag-
nosis was made at the CBC.
Data analysis
Data was entered into a Microsoft Access database and
analyzed using STATA v.13. Descriptive statistics
(means, medians, proportions) were used to characterize
the variables. Crude bivariate comparisons (using Wil-
coxon rank-sum and Kruskal-Wallis tests to compare
medians and ranked distributions, and Yates corrected
chi-square and Fisher’s Exact test to compare propor-
tions) were used to identify factors associated with stage
at presentation (early versus late). Multivariate logistic
regression was used to identify independent factors asso-
ciated with late stage presentation. Variables included in
the model were those significant with bivariate analysis
and those of a priori interest. The final model included:
age (categorized using the median); educational level;
marital status; employment status; composite unprompted
knowledge score, first symptom (lump vs. other) and men-
tion of pain as a reason for seeking care.
Crude bivariate comparisons (using Wilcoxon rank-sum
and Kruskal-Wallis tests to compare medians and ranked
distributions, and Yates corrected chi-square and Fisher’s
Exact test to compare proportions) were used to identify
factors associated with a total time from first change to
scheduled treatment of > 3 months. Multivariable logistic
regression analysis was conducted to determine independ-
ent predictors of a total time of > 3 months. Variables sig-
nificant with analysis (p < 0.05), and those of a priori
interest were included in the model: age (categorized
using the median); educational level; composite un-
prompted knowledge score; first change noticed (breast
lump or other); type of health care provider seen (public
sector, private sector or other); mention of increase in
lump size as a reason for seeking care; mention of concern
about breast changes as a reason for seeking care and;
stage at presentation.
For the PI, DI and PTI a bivariate comparison of me-
dian time intervals by various characteristics was con-
ducted using Wilcoxon rank-sum and Kruskal-Wallis
tests to compare medians and ranked distributions. Cox
Proportional-Hazards models were used to establish fac-
tors independently associated with the PI, DI and PTI.
All Cox regression models included variables that were
significant with bivariate analysis (p < 0.05), and variables
of a priori interest. For the PI regression model variables
included were: age (categorized using the median);
educational level; marital status; unprompted composite
knowledge score; history of co-morbidities (benign
breast disease, any other co-morbidity, no co-morbidity);
stage of disease (early or late); first change noticed
(breast lump or other); thought first change was breast
cancer; ignored first breast change; thought first change
was minor/not serious; mention of family or friends as a
being a reason for seeking care; mention of increase in
lump size as a reason for seeking care and; mention of
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concern about breast change as a reason for seeking
care. For the DI regression model variables included
were: age (categorized using the median); educational
level; history of co-morbidities (benign breast disease,
any other co-morbidity, no co-morbidity); first change
noticed (breast lump or other); mention of denial as ini-
tial response to breast change; stage of disease (early or
late) and; type of health care provider first seen (public
or private sector). The PTI regression model included
the following variables: age (categorized using the me-
dian); educational level; stage of disease (early or late)
and type of first treatment (surgery or other).
Ethical approval to conduct the study was obtained
from the Human Research Ethics Committee, University
of Cape Town (Reference number 313/2013). Written
informed consent was obtained from all participants.
Results
A total of 216 women were approached to participate in
the study: 8 refused (1 due to time constraints, 1 did not
feel emotionally ready, 5 were not interested in the re-
search study) and 7 were ineligible. The median age of
the 201 participants was 54 years, interquartile range
(IQR) 45–63. Table 1 outlines the socio-demographic
profile of the participants. The majority of women had a
high school or higher educational level and 75% were
unemployed.
Knowledge of breast cancer risk factors and signs
Women had very limited knowledge of breast cancer
risk factors. In response to the unprompted question i.e.
“Can you name as many risk factors of breast cancer
that you can think of,” 67% of woman could not name a
single risk factor. The most commonly recognized risk
factor was a family history of breast cancer: 25% and
74% of women in the open and closed question respect-
ively (see Fig. 1). Most women were aware that a breast
or armpit lump was a sign of breast cancer. When
unprompted i.e. in response to the open question “Can
you name as many signs factors of breast cancer that
you can think of”, knowledge of other breast cancer
signs was limited (see Fig. 2).
Symptom appraisal
For the majority (74%) of women the first symptom no-
ticed was a breast lump, 8% reported pain in the breast
or armpit as the first symptom, 7% noticed a change in
breast size, 4% reported nipple changes and 3% a lump
in the armpit as the first change. Fifty percent of women
appraised the first symptom as being minor or not ser-
ious, 31% thought it could be breast cancer and 4% re-
ported being in denial. Once a symptom was noticed the
main reasons for seeking health care included: wanting
to make sure nothing was wrong (61%); persuasion by
family members and friends (50%); pain (29%) and; be-
cause the lump was getting bigger (25%). The majority
(72%) of women first had their symptom assessed at a
public sector primary health care service.
Clinical history and profile
A history of co-morbidities was fairly common: 47% of
women gave a history of hypertension, 13% had benign
breast disease and 12% reported having diabetes. Thirty-
eight percent of women had a family history of breast
cancer. Just over half (55%) of the women interviewed
stated that they were in the habit of checking their
breasts, with the vast majority of these women reporting
breast self-examination at least once a month. The com-
monest histological subtype observed was invasive ductal
carcinoma (77%) and 14% of women had triple negative
disease. Twenty-two percent of women presented with
late stage (stages III and IV) disease. Using bivariate
Table 1 Socio-demographic profile of participants
Characteristic Total (201)
n (%)
Main Home Language
English 68 (33.8)
Afrikaans 80 (39.8)
Xhosa 45 (22.4)
Other 8 (4.0)
Education level
None-Grade 7 49 (24.4)
Grade 8-Grade 11 96 (47.8)
Grade 12+ 56 (27.9)
Marital status
Married 84 (41.8)
Single in stable relationship 6 (3.0)
Single 42 (20.9)
Widowed 38 (18.9)
Divorced/separated 31 (15.4)
Employed 51 (25.4)
Have medical insurance 6 (3.0)
Ever smoked 45 (22.5)
Ever drank alcohol 12 (6.2)
Household income statusa
H0 66 (32.8)
H1 81 (40.3)
H2 32 (15.9)
H3 19 (9.5)
a3 records missing.
H0: persons on social grant; H1: individual income < $5366 per annum (p.a.) or
family income < $7667 p.a.; H2: individual income between $5367 and $19,168
p.a. or family income between $7667 and $26,852 p.a.; and H3: individual
income >$19,168 p.a. or family income > $26,852 p.a
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analysis being single vs. being married [15 (36%) vs. 18
(21%), p = 0.034], first symptom not being a lump vs.
lump [19 (37%) vs. 25 (17%), p = 0.004] and mention of
pain as a reason for seeking care vs. not mentioned [19
(33%) vs. 25 (18%), p = (0.019] were all associated with
late stage at presentation. On multivariate analysis, none
of these factors remained significant at the 0.05 cut-off
level (being single vs. being married adjusted Odds Ratio
(aOR) 2.20, 95% CI 0.89–5.42, p = 0.087; first symptom
not being a lump vs. lump aOR 0.47, 95% CI 0.21–1.04, p
= 0.064; mention of pain as a reason for seeking care vs.
not mentioned aOR 1.97, 95% CI 0.88–4.41, p = 0.097).
Key time intervals in the pathway to diagnosis and
treatment
The overall median time from first symptom discovery to
initiation of treatment was 110 days (IQR 67–178). For
60% of patients the time between symptom discovery and
treatment initiation exceeded 3 months. Compared to
those with shorter time from symptom discovery to
treatment i.e. ≤ 3 months), those with a longer interval
were significantly more likely to mention seeking care be-
cause the lump was getting bigger aOR 2.7 95% confi-
dence interval (CI) 1.15–6.12) and less likely to mention
that they sought medical care because they were worried
about the initial changes (aOR 0.30, 95% CI 0.15–0.61).
Details on the patient, diagnostic and pre-treatment inter-
vals and associated factors are provided below.
Patient interval
The median patient interval was 23 days, IQR 6–
64 days. Women whose interpretation of the initial
symptom as possibly being breast cancer and women
who mentioned concern about the symptom as a rea-
son for seeking care had a significantly shorter median
PI (Table 2). Initial denial of symptoms, appraising the
symptom as minor, being prompted by family members
or friend to seek care and only seeking care when a
lump increased in size were associated with signifi-
cantly longer PI intervals (Table 2). On regression
Fig. 1 Unprompted and prompted knowledge of breast cancer risk factors
Fig. 2 Unprompted and prompted knowledge of breast cancer signs
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analysis older age (HR 0.59, 95% CI 0.40–0.86); those
who initially denied symptoms (HR 0.43, 95% CI 0.19–
0.97); those who sought care to check that nothing was
wrong (HR 1.76, 95% CI 1.20–2.58) and those waited
for a lump to increase in size before seeking care (HR
Table 2 Association between participant characteristics and
patient interval (n = 187)
Variable Patient interval
N Median p-value
Agea
Age≤ 54 years 95 21 0.355
Age > 54 years 90 29
Education
None-Grade 7 43 35 0.807
Grade 8-Grade 11 91 22
Grade 12+ 53 23
Marital status
Married 76 31 0.163
In stable relationship 6 10
Single 41 15
Widowed 35 26
Divorced/separated 29 33
Paid work
Yes 48 15 0.064
No 139 28
Income statusb
H0 59 32 0.668
H1 76 17
H2 30 19
H3 19 33
Composite unprompted knowledge
None 14 21.5 0.308
Very little 160 23
Little 13 19
History of co morbidities
Benign breast disease/fibroadenoma 23 23 0.522
Any other co-morbidity 104 22
None 60 32
Family history of breast cancer
Yes 74 23 0.953
No 97 23
Not sure 16 19
Habit of checking breasts for lumps/changes
Yes 105 20 0.087
No 82 31
First breast change notice
Lump 140 22 0.785
Other changes 47 23
Appraisal of first change
Thought it was not serious/minor
Mentioned 92 33 0.027
Table 2 Association between participant characteristics and
patient interval (n = 187) (Continued)
Variable Patient interval
N Median p-value
Not mentioned 95 15
Thought it was breast cancer
Mentioned 59 12 0.005
Not mentioned 128 31
Not sure what change meant
Mentioned 109 27 0.413
Not mentioned 78 20
Ignored it/was in denial
Mentioned 7 111 0.003
Not mentioned 180 22
Reason to have symptom checked
Felt painc
Mentioned 54 27 0.550
Not mentioned 132 22
Lump was increasing in sizec
Mentioned 47 52 0.001
Not mentioned 139 15
Prompted by family/friendsc
Mentioned 92 31.5 0.053
Not mentioned 94 15
Prompted by pamphlet/breast cancer awareness
event/TV programc
Mentioned 50 25 0.719
Not mentioned 136 22
Wanted to be sure nothing was wrongc
Mentioned 112 18 0.046
Not mentioned 74 34
First health care provider seen
Public sector primary health care clinic or
district hospital
138 27 0.095
Private practitioner 45 12
Other 4 45
Cancer stage
Early (stage 1&2) 144 20 0.199
Late (stage 3&4) 43 33
a 2 records missing, b 3 records missing, c 1 record missing.
H0: persons on social grant; H1: individual income < $5366 per annum (p.a.) or
family income < $7667 p.a.; H2: individual income between $5367 and $19,168
p.a. or family income between $7667 and $26,852 p.a.; and H3: individual
income >$19,168 p.a. or family income > $26,852 p.a
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0.51, 95% CI 0.33–0.77) were significant factors (see
Additional file 2).
Diagnostic interval
The median time between the first health care visit and
a breast cancer diagnosis was 28 days (IQR 13–58 days).
Fifty-four percent of women had made 4 or more health
care visits between symptom discovery and a breast can-
cer diagnosis, whilst 11% made 6 or more visits. Using
bivariate analysis (Table 3) women who first appraised
the symptom as being minor compared to those that did
not (32 days vs. 22 days, p = 0.047) and, women with a
past history of benign breast disease, or a history of
other co-morbidities had a significantly longer diagnostic
interval compared to those with no co-morbidities (me-
dian interval 48, 29 and 20 days respectively, p = 0.004);
whilst women whose initial reaction was denial of the
breast symptom had a significantly shorter diagnostic
interval (11 days vs. 29 days, p = 0.010). When adjusted
for other factors (Cox regression analysis), a history of
other co-morbidities HR 0.67, 95% CI (0.47–0.96) and
denial of initial breast symptoms (HR 4.61, 95% CI
1.80–11.78) remained significant (see Additional file 3).
Pre-treatment interval
The median time from diagnosis to date of scheduled
treatment was 37 days, IQR 18–50 days. Women with
late stage disease had a significantly shorter PTI com-
pared to women with early stage disease (median 21 days
vs. 40 days, p = 0.001), whilst women with surgery as op-
posed to other types of treatment had a longer PTI (me-
dian 40 days vs. 15 days, p = 0.002) and women whose
first line of treatment was chemotherapy as compared to
first modes of treatment had a shorter median PTI
(14 days vs. 40 days, p < 0.001) (Table 4). When adjusted
for other factors using Cox regression, late stage of dis-
ease at presentation remained significant (HR 1.78, 95%
CI 1.15–2.76, p = 0.010), see Additional file 4.
Discussion
Our study is the first in South Africa quantifying time
intervals and associated factors between symptom detec-
tion and breast cancer treatment, using the Model of
Pathways to Treatment as a guiding framework [16].
Key factors influencing the journey to care were: limited
knowledge of breast cancer risk factors and signs; sub-
optimal symptom interpretation and appraisal; waiting
for symptoms to worsen before seeking care; and the
presence of co-morbidities.
Across all cancer sites, non-recognition of the serious-
ness of cancer symptoms has been shown to be an im-
portant risk factor for delays in seeking care [19]. For
breast cancer knowledge, awareness and risk perception
all influence initial symptom interpretation [20]. Among
our patients, knowledge of breast cancer risk factors and
symptoms was low, pointing to a clear need for targeted
interventions to improve knowledge as this may hasten
help-seeking behavior. Despite this low level of know-
ledge of breast cancer symptoms, a significant propor-
tion of women reported practicing regular breast self-
examination. This finding is of concern as it would be
assumed that programs promoting breast self- examin-
ation would also be teaching women about risk factors
and all signs of breast cancer. Perhaps this finding
should prompt a refocus of breast awareness campaigns
to emphasize all signs of breast cancer rather than only
emphasizing breast self-examination. This shift would be
in keeping with the change in policy in the US and UK
from promoting regular breast self-examination to pro-
moting breast awareness [21, 22]. The incongruence be-
tween our findings of poor knowledge of signs and
regular breast self-examination could also be due to so-
cial desirability bias. A recent Cochrane review reported
that brief interventions have the potential to increase
breast awareness among women, although further stud-
ies are required to validate this [23]. Encouragingly, a
study in Malaysia demonstrated that a public breast can-
cer awareness program coupled with staff training re-
duced late stage presentation of breast cancer by half
over a four- year period [24].
Time intervals are often reported on as “time delays”
in the literature. This incorrectly can imply a decision
for inaction; however, the extensive use of “time delay”
in the literature makes it difficult to avoid the term in
this report. The association between time from symptom
detection to cancer treatment, often referred to as the
total time delay, and survival is complex [25–28]. A
landmark systematic review of 87 breast cancer studies
showed that a delay of > 3 months was associated with
worse survival, compared to treatment within 3 months
of symptom detection (OR 1.47, 95% CI 1.42–1.53) [29].
Recent studies have however produced mixed results but
many did not take into account differences in tumour
growth and the confounding effect of lead-time bias [25,
30]. A further complication in interpreting the associ-
ation between time intervals and outcome is the range
of methods used to measure time points and events,
making comparison of studies difficult. Whilst it may be
difficult to quantify the benefit on survival, recognized
benefits of earlier time to treatment include, earlier stage
at diagnosis, decreased morbidity and symptom relief
[26, 27], thus reducing time delays is of importance.
Studies on intervals to treatment for women with
breast cancer show marked differences between LMIC
and high-income countries (HIC)s. A review of time in-
tervals for breast cancer patients in10 HICs and LMICs
[28] showed that among HICs, the median total time
interval ranged between 1 to 1.6 months with more than
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60% of patients commencing treatment less than
3 months from discovery. In comparison, the median
total time interval for LMICs was between 5.5 to
8 months with fewer than 30% of patients starting treat-
ment within 3 months of symptom discovery [28] .In
Table 3 Association between participant characteristics and
diagnostic interval (n = 193)
Variable Diagnostic interval
N Median p-value
Agea
Age≤ 54 years 95 23 0.370
Age > 54 years 96 30
Education
None-Grade 7 48 30 0.839
Grade 8-Grade 11 93 23
Grade 12+ 52 25
Marital status
Married 82 29 0.673
In stable relationship 6 15
Single 40 23
Widowed 34 28
Divorced/separated 31 22
Paid work
Yes 50 27 0.654
No 143 28
Income statusb
H0 63 34 0.757
H1 76 23
H2 32 27
H3 19 22
Composite unprompted knowledgea
None 16 24 0.300
Very little 164 25
Little 13 34
History of co-morbidities
History of benign breast disease/fibroadenoma 24 48 0.004
Any other co-morbidity 105 29
None 64 20
Family history of breast cancer
Yes 75 23 0.635
No 100 28
Not sure 18 35
Habit of checking breasts for lumps/changes
Yes 108 30 0.172
No 85 25
First breast change noticedc
Lump in breast 140 23 0.155
Other changes 49 34
Appraisal of first change
Thought it was not serious/minorc 0.047
Mentioned 94 31.5
Table 3 Association between participant characteristics and
diagnostic interval (n = 193) (Continued)
Variable Diagnostic interval
N Median p-value
Not mentioned 95 22
Thought it was breast cancer c
Mentioned 58 22 0.346
Not mentioned 131 29
Not sure what change meantc
Mentioned 115 27 0.206
Not mentioned 74 26
Ignored it/was in denial
Mentioned 6 11 0.010
Not mentioned 187 29
Reason to have symptom checked
Felt paind
Mentioned 56 30 0.443
Not mentioned 132 23
Lump was increasing in sized
Mentioned 47 23 0.459
Not mentioned 141 29
Prompted by family/friendsd
Mentioned 94 23 0.486
Not mentioned 94 30
Prompted by pamphlet/breast cancer awareness
event/TV programd
Mentioned 48 21 0.317
Not mentioned 140 29
Wanted to be sure nothing was wrongd
Mentioned 116 23 0.180
Not mentioned 72 34
First health care provider seenb
Public sector primary health care clinic or
district hospitalb
138 30 0.510
Private practitioner 48 24
Other 4 14
Cancer stage
Early (stage 1&2) 154 28 0.825
Late (stage 3&4) 39 21
a 2 missing records, b 3 missing records, c 4 missing records, d 5 missing records.
H0: persons on social grant; H1: individual income < $5366 per annum (p.a.) or
family income < $7667 p.a.; H2: individual income between $5367 and $19,168
p.a. or family income between $7667 and $26,852 p.a.; and H3: individual
income >$19,168 p.a. or family income > $26,852 p.a
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this report total time interval data were not available for
the few African countries included in the review [28].
Another meta-analysis of delays in breast cancer diagno-
sis and treatment conducted in 12 LMICs reported a
mean total delay time of 3.6 months [7] . Median time
delays were not reported and no African country data
was included in the latter analyses. The only African
study describing total median breast cancer delay times
was conducted in Rwanda and documented a total time
delay of 15 months – the longest ever recorded in the
literature [31]. In our study, the median total time from
symptom discovery to scheduled treatment was
3.9 months (110 days/ 15.7 weeks), with 60% of patients
commencing treatment after 3 months i.e. shorter than
median total delay times reported for LMICs by Unger-
Saldana et al. [28] and Pace et al. [31] but considerably
longer than that reported for HICs. Factors associated
with the delay of > 3 months were related to symptom
appraisal and included waiting for symptom progression
before seeking care and a lack of initial concern about
the symptom. These results are consistent with findings
in an earlier qualitative study conducted in our hospital
setting in which women reported a period of monitoring
symptoms before deciding to seek care and did not per-
ceive their initial breast symptoms as abnormal [13].
For breast cancer, the PI i.e. the time between symp-
tom discovery and first presentation to a health care
provider, differs widely between HICs and LMICs, with
intervals as low as 7 days (median) reported in the UK
[32] and as high as 11.9 months (mean) in Sudan [12].
In comparison, the median PI in our study was 23 days.
Factors significantly associated with a longer PI included
older women, those reporting initial denial of symptoms
and women who waited for their lump to increase in size
before seeking care. All of these have been reported pre-
viously in the literature as being associated with a longer
PI [20, 33]. Our findings suggest that interventions to
decrease the PI need to target older women and stress
the importance of immediate help-seeking for symptoms
rather than adopting a wait-and-see approach.
The median time of 28 days between first presentation
to a health facility and diagnosis (diagnostic interval) in
our study is well within the SA policy recommendation
of 60 days [4]. It is also much shorter than that reported
in other LMICs: median of 94 days in Brazil [14]; me-
dian of 150 days in Rwanda [31]; mean of 70 days in
KwaZulu-Natal (KZN) South Africa [34] and; mean of
78 days in 12 LMICs [7]. The difference in DI between
our study and the only other SA study reporting on
diagnostic delay [34] is likely, in part, to be related to
the benefit of our breast clinic being an open-access
clinic, not requiring staging and work-up pre-referral,
which is required is the KZN setting. Our findings point
to the benefit of specialist breast units for diagnosis and
Table 4 Association between participant characteristics and
pre-treatment interval (n = 192)
Variable Pre-treatment interval
N Median p-value
Agea
Age≤ 54 years 95 37 0.795
Age > 54 years 95 35
Education
None-Grade 7 47 21 0.044
Grade 8-Grade 11 92 41
Grade 12+ 53 40
Marital status
Married 83 42 0.344
In stable relationship 6 18
Single 39 28
Widowed 34 29
Divorced/separated 30 37
Paid work
Yes 51 37 0.860
No 141 35
Income statusb
H0 62 39 0.415
H1 76 33
H2 32 35
H3 19 30
Co-morbidities
History of benign breast disease/fibroadenoma 24 36 0.538
Any other co-morbidity 106 34
None 62 40
Cancer stage
Early (stage 1&2) 154 40 0.001
Late (stage 3&4) 38 21
First treatment surgeryc
Yes 157 40 0.002
No 34 15
First treatment chemotherapyc
Yes 27 14 < 0.001
No 164 40
First treatment hormonal therapyc
Yes 13 28 0.753
No 178 36
First treatment radiotherapyc
Yes 2 91 0.105
No 189 35
a 2 records missing, b 3 records missing, c 1 record missing.
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management of breast disease, together with easy access
to multi-disciplinary provincial oncology units – an ap-
proach that is in keeping with the new SA breast cancer
prevention and control policy [4]. Half of the partici-
pants in our study however still made 4 or more visits to
a health care provider before being referred to the one-
stop breast clinic at the tertiary hospital. Reasons for the
multiple visits before referral need to be explored. Inter-
estingly patients whose initial reaction was one of denial
had a significantly shorter diagnostic interval i.e. time
between symptom detection and diagnosis. Further re-
search is required to confirm this finding and explore
how patient’s reactions to symptoms influence provider
referral patterns. Of concern is the fact that women with
co-morbidities, who would have had greater contact with
the primary health care services, had a longer diagnostic
interval compared to those without co-morbidities. Re-
search exploring primary health care providers’ knowledge
of risk factors and symptoms as well as challenges in man-
aging and referring patients with potential symptoms of
breast symptoms could help identify potential targets for
interventions to further reduce the diagnostic interval.
For our patients, the longest interval in their journey
to treatment was the pre-treatment interval – defined as
the time between diagnosis and scheduled treatment
(median 37 days). In our study women who required
surgery as their first mode of treatment, had significantly
longer waiting times than those requiring other modes
of treatment. Our median waiting time of 40 days for
surgical treatment post diagnosis is within the waiting
time of less than 6 weeks from first diagnostic visit to
definitive treatment suggested by both the European So-
ciety of Breast Cancer Specialist [35] and the UK Na-
tional Health Service Guidelines [36], but longer than
the SA policy recommendation of 31 days [4]. The me-
dian waiting time to surgery of 40 days reported in our
study is achieved by the use of extra breast cancer the-
atre lists (Breast Cancer Project Lists) which are run by
the Breast Surgical Unit in partnership with Groote
Schuur Hospital and Project Flamingo (a non-profit
organization dedicated to improving access to breast
cancer treatment). These Project Lists take place on
weekends and public holidays and between 8 and 12
extra full day lists are done per year. In the absence of
these voluntary extra lists, the waiting time for surgery
using the state health sector theatre resources alone
would be approximately 12 weeks (84 days) (personal
communication L Cairncross, Groote Schuur Hospital).
This waiting time also does not take into consideration
the fact that most women who are eligible for breast re-
construction cannot be offered this service due to pres-
sures on theatre resources. The recommendation of
31 days outlined in the SA breast cancer prevention and
control policy would need a considerable injection of
resources in order to be met by most public-sector insti-
tutions in SA.
Our study has limitations. Due to logistic constraints
we were unable to recruit to target (target = 213, number
recruited = 201), and results need to be interpreted with
this in mind. Retrospective recall could have affected ac-
curate reporting of symptoms and health seeking behav-
ior in our study. We sought to minimize this through
the use of a calendar prompt and conducting interviews
soon after diagnosis. However, the timing of interviews
could also have resulted in difficulty in putting the jour-
ney into perspective if women were not emotionally pre-
pared for this. Further, interviews conducted in a
hospital setting could have resulted in a social desirabil-
ity bias with under-reporting of time delays and over
reporting of desirable behavior such as breast self-
examination. We recognize that the time intervals re-
ported are unlikely to be representative of intervals seen
in public sector settings in SA without a tertiary centre-
based one-stop breast clinic. However, results point to
the potential intervals that can be achieved with one-
stop specialized breast units.
Conclusion
The Model of Pathways to Treatment provides a useful
framework to explore patient’s journeys to care. Our
study identified targets for interventions that could im-
prove time to diagnosis. These include interventions
that: address women’s limited knowledge of breast can-
cer risk factors and symptoms; promote breast aware-
ness; target older women; address denial; encourage
prompt help-seeking behaviour and educate women not
to wait for a lump to get bigger or be painful before
seeking care.
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